Previous Page  7 / 34 Next Page
Information
Show Menu
Previous Page 7 / 34 Next Page
Page Background

Page 44

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

16

th

EuroSciCon Conference on

Immunology

M a r c h 1 1 - 1 2 , 2 0 1 9

Am s t e r d a m , N e t h e r l a n d s

Immunology 2019

Martin Ungerer, J Clin Immunol Allergy 2019, Volume:5

DOI: 10.21767/2471-304X-C1-009

G

raves’ disease is an autoimmune disorder, which is characterized by

stimulatory antibodies targeting the human thyrotropin receptor (TSHR),

resulting in hyperthyroidism and multiple organ damage. The disease can

be modelled in mice using adenoviral immunizations with the extracellular A

subunit of the TSHR, which induces a long-term stable disease state. TSHR

binding cAMP-stimulatory antibodies, thyroid enlargement, elevated serum

thyroxin levels, tachycardia, cardiac hypertrophy and orbitopathy are observed

in these Ad-TSHR-immunized mice. T cell epitope-derived linear peptides

have been identified using immunized HLA-DR3 transgenic mice, which may

induce tolerance towards TSHR at the group of David Wraith, Birmingham, UK.

A combination of such peptides have being investigated in a first clinical phase

I trial with encouraging results in patients with Graves´ disease at Apitope Inc.

Alternatively, cyclic peptides derived from the interaction site of the TSHR A

domain with stimulatory anti-TSHR antibodies were injected intravenously in

monthly intervals into mice modelling Graves´ disease. These administrations

of cyclic peptides were each timed two weeks after the respective Ad-TSHR

immunizations, and re-established tolerance towards the antigen, improving

symptoms of Graves´ disease within 3 – 4 months after starting these

therapies. In immunologically naïve mice, administration of the cyclic peptides

did not induce any immune response.

Biography

Medical school at the University of Munich, Germany, and at the

Universities of Marseille and Nice, France post-doc in the lab

of Prof. Martin Lohse and Prof. Ernst Winnacker, Gene Center,

Max-Planck-Institute for Biochemistry, Martinsried, Germany

Resident/Senior House Officer at the1st Medical Clinic Rechts

der Isar and German Heart Center, TUM University of Munich,

training in internal medicine and cardiology Phd promotion

("Habilitation") at TUM University of Munich. Founder and

member of the company management of ProCorde GmbH,

CorimmunGmbHand advanceCORGmbH- biotech companies

which established novel technologies and drugs for the

treatment of thrombosis, cardiac and immunological diseases

approved professor of internal medicine and cardiology at

the University of Würzburg member of the „Translational

Research Group“ steering committee of the German Centre for

Cardiovascular Research, Berlin.

ungerer@advancecor.com

Induction of tolerance for antigen-specific therapy of Graves´

disease and orbitopathy

Martin Ungerer

AdvanceCOR-GmbH, Germany